EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy

Thomas M Atkinson, Jennifer L Hay, Soo Young Kim, Elizabeth Schofield, Michael A Postow, Parisa Momtaz, Allison Betof Warner, Alexander N Shoushtari, Margaret K Callahan, Jedd D Wolchok, Yuelin Li, Paul B Chapman iD

The Oncologist · 06.04.2023 · 28 (4) · 351-357

DOI: 10.1093/oncolo/oyac266 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 06.02.2023. Verfasst von Thomas M Atkinson und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry & Behavior Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NCI, Parker Institute for Cancer Immunotherapy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Adjuvant anti-PD1 treatment improves relapse-free survival (RFS) but has not been shown to improve overall survival (OS) in melanoma and is associated with risks of immune-related adverse events (irAEs), some permanent. We identified factors patients consider in deciding whether to undergo adjuvant anti-PD1 treatment and assessed prospective health-related quality of life (HRQoL), treatment satisfaction, and decisional regret. Patients and Methods Patients with stage IIIB-IV cutaneous melanoma and free of disease, were candidates for adjuvant anti-PD1 immunotherapy, and had not yet discussed adjuvant treatment options with their oncologist were eligible. Participants viewed a 4-minute informational video tailored to their disease stage which communicated comprehensive, quantitative information about the risk of relapse both with and without adjuvant treatment, and risks of each irAE before deciding whether or not to opt for adjuvant therapy. We collected data on demographics, HRQoL, and attitudes toward adjuvant treatment over 1 year.

Results

14/34 patients (41%) opted for adjuvant anti-PD1 immunotherapy, 20/34 (59%) opted for observation. Patients choosing adjuvant immunotherapy scored higher on HRQoL social well-being at pre-treatment, were more likely to endorse positive statements about adjuvant immunotherapy, and to perceive that their physician preferred adjuvant therapy. They had lower decisional regret and higher satisfaction, even if they experienced toxicity or recurrence.

Conclusions

When provided with comprehensive quantitative information about risks and benefits of adjuvant anti-PD1 immunotherapy, 20/34 (59%) of patients opted for observation. Patients choosing adjuvant immunotherapy had lower decisional regret and higher satisfaction over time even if they had poorer outcomes in treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsHumansQuality of LifeNeoplasm Recurrence, LocalImmunotherapyCutaneous Malignant Melanoma

Autor:innen und Institutionen

  • Department of Psychiatry & Behavior Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Weill Cornell Medical College, New York, NY, USA.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Ludwig Institute for Cancer Research, New York, NY, USA.

ORCID-Profile: Paul B Chapman

Förderung

  • NCI NIH HHS
  • NCI
  • Parker Institute for Cancer Immunotherapy

Zitieren

APA

Atkinson, T. M., Hay, J. L., Young Kim, S., Schofield, E., Postow, M. A., Momtaz, P., Warner, A. B., Shoushtari, A. N., Callahan, M. K., Wolchok, J. D., Li, Y., & Chapman, P. B. (2023). Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy. The Oncologist, 28(4), 351-357. https://doi.org/10.1093/oncolo/oyac266

Vancouver

Atkinson TM, Hay JL, Young Kim S, Schofield E, Postow MA, Momtaz P, et al. Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy. The Oncologist. 2023;28(4):351-357. doi:10.1093/oncolo/oyac266

BibTeX
@article{Atkinson2023,
  author = {Atkinson, Thomas M and Hay, Jennifer L and Young Kim, Soo and Schofield, Elizabeth and Postow, Michael A and Momtaz, Parisa and Warner, Allison Betof and Shoushtari, Alexander N and Callahan, Margaret K and Wolchok, Jedd D and Li, Yuelin and Chapman, Paul B},
  title = {Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy},
  journal = {The Oncologist},
  year = {2023},
  volume = {28},
  number = {4},
  pages = {351--357},
  doi = {10.1093/oncolo/oyac266}
}
Kostenlos starten →